Preventing the development of early stage prostate cancer
Initially, Evgen is developing Sulforadex® for the prevention of early stage prostate cancer disease progression.
Elevated PSA (a test for prostate cancer risk) can lead to a biopsy whereupon a clinical diagnosis can be made. Patients determined to be positive for an indolent form of the disease, will continue to be monitored by urologists but there is currently no established standard of care.
A cost effective pharmaceutical with a low toxicity profile and minimal side effects, which successfully retards the histological progression of indolent disease, would have a major impact on disease-associated cost, morbidity, and mortality for a large segment of the male population. Such a pharmaceutical would be expected to drive a paradigm shift toward prophylaxis, and concurrent growth, of the current $5.5bn prostate cancer therapeutic market.
Other markets
In addition to potentially reducing the progression of some early stage cancers, sulforaphane has also been linked to the potential treatment of more aggressive cancers as a potential adjunct to existing standards of care. Also, sulforaphane has been linked to the eradication of H. pylori, delaying age-related macular degeneration (AMD), reversal of diabetic heart damage and reduction of risk of cardiovascular disease.